In patients with HR/HER2-advanced breast cancer after progression on the CDK4/6 inhibitor, the patients who applied endocrine therapy in combination with the mTOR inhibitor had a median PFS benefit of 5.1 months (115). This evidence concerns the gene ERBB2 and breast carcinoma.